Association of fibrotic markers with diastolic function after STEMI.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 Aug 2024
18 Aug 2024
Historique:
received:
19
09
2023
accepted:
10
08
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
18
8
2024
Statut:
epublish
Résumé
Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.
Identifiants
pubmed: 39155333
doi: 10.1038/s41598-024-69926-y
pii: 10.1038/s41598-024-69926-y
doi:
Substances chimiques
Biomarkers
0
Interleukin-1 Receptor-Like 1 Protein
0
IL1RL1 protein, human
0
Galectin 3
0
Galectins
0
LGALS3 protein, human
0
Blood Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19122Subventions
Organisme : ZonMw,Netherlands
ID : 95103007
Informations de copyright
© 2024. The Author(s).
Références
Talman, V. & Ruskoaho, H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 365, 563–581 (2016).
doi: 10.1007/s00441-016-2431-9
pubmed: 27324127
pmcid: 5010608
Kakkar, R. & Lee, R. T. The IL-33/ST2 pathway: Therapeutic target and novel biomarker. Nat. Rev. Drug Discov. 7, 827–840 (2008).
doi: 10.1038/nrd2660
pubmed: 18827826
pmcid: 4277436
Weinberg, E. O. et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107, 721–726 (2003).
doi: 10.1161/01.CIR.0000047274.66749.FE
pubmed: 12578875
Liu, F. T. et al. Expression and function of galectin-3, a β-galactoside-binding lectin, in human monocytes and macrophages. Am. J. Pathol. 147, 1016–1028 (1995).
pubmed: 7573347
pmcid: 1871012
Sharma, U. C. et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110, 3121–3128 (2004).
doi: 10.1161/01.CIR.0000147181.65298.4D
pubmed: 15520318
Meijers, W. C. et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. Am. Heart J. 167, 853 (2014).
doi: 10.1016/j.ahj.2014.02.011
pubmed: 24890535
de Boer, R. A. et al. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 272, 55–64 (2012).
doi: 10.1111/j.1365-2796.2011.02476.x
pubmed: 22026577
van der Velde, A. R. et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin. Chim. Acta. 452, 50–57 (2016).
doi: 10.1016/j.cca.2015.10.034
pubmed: 26528636
Lexis, C. P. H. et al. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: Rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc. Drugs Ther. 26, 417–426 (2012).
doi: 10.1007/s10557-012-6413-1
pubmed: 22968678
pmcid: 3464381
Lexis, C. P. H. et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: The GIPS-III randomized clinical trial. JAMA 311, 1526–1535 (2014).
doi: 10.1001/jama.2014.3315
pubmed: 24687169
Al Ali, L. et al. The effect of metformin on diastolic function in patients presenting with ST-elevation myocardial infarction. PLoS One 11, e0168340 (2016).
doi: 10.1371/journal.pone.0168340
pubmed: 27977774
pmcid: 5158040
Meijers, W. C., Van Der Velde, A. R. & De Boer, R. A. The ARCHITECT galectin-3 assay: Comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. Expert Rev. Mol. Diagn. 14, 257–266 (2014).
doi: 10.1586/14737159.2014.892421
pubmed: 24606321
Christenson, R. H. et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin. Biochem. 43, 683–690 (2010).
doi: 10.1016/j.clinbiochem.2010.02.001
pubmed: 20153309
Mueller, T. & Dieplinger, B. The Presage(®) ST2 Assay: Analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev. Mol. Diagn. 13, 13–30 (2013).
doi: 10.1586/erm.12.128
pubmed: 23256700
Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur. J. Echocardiogr. 10, 165–193 (2009).
doi: 10.1093/ejechocard/jep007
pubmed: 19270053
Lang, R. M. et al. Recommendations for chamber quantification. Eur. J. Echocardiogr. 7, 79–108 (2006).
doi: 10.1016/j.euje.2005.12.014
pubmed: 16458610
Devereux, R. B. et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am. J. Cardiol. 57, 450–458 (1986).
doi: 10.1016/0002-9149(86)90771-X
pubmed: 2936235
Du Bois, D. & Du Bois, E. F. A formula to estimate the approximate surface area if height and weight be known. Nutrition 5, 303–311 (1916) (Discussion 312–313 (1989)).
Pieske, B. et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 40, 3297–3317 (2019).
doi: 10.1093/eurheartj/ehz641
pubmed: 31504452
Hummel, Y. M. et al. Diastolic function measurements and diagnostic consequences: A comparison of pulsed wave- and color-coded tissue Doppler imaging. Clin. Res. Cardiol. 99, 453–458 (2010).
doi: 10.1007/s00392-010-0141-y
pubmed: 20221616
pmcid: 2898098
Benjamin, D. J. et al. Redefine statistical significance. Nat. Hum. Behav. 2, 6–10 (2018).
doi: 10.1038/s41562-017-0189-z
pubmed: 30980045
Johnson, J. A. Diastolic dysfunction in congestive heart failure. N. Engl. J. Med. 325, 850–861 (1991).
Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E. & Blaxall, B. C. Cardiac fibrosis: The fibroblast awakens. Circ. Res. 118, 1021–1040 (2016).
doi: 10.1161/CIRCRESAHA.115.306565
pubmed: 26987915
pmcid: 4800485
Weisman, H. F., Bush, D. E., Mannisi, J. A. & Bulkley, B. H. Global cardiac remodeling after acute myocardial infarction: A study in the rat model. J. Am. Coll. Cardiol. 5, 1355–1362 (1985).
doi: 10.1016/S0735-1097(85)80348-X
pubmed: 3158687
Manhenke, C. et al. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int. J. Cardiol. 150, 277–282 (2011).
doi: 10.1016/j.ijcard.2010.04.034
pubmed: 20493567
Screever, E. M. et al. Diffuse myocardial fibrosis on cardiac magnetic resonance imaging is related to Galectin-3 and predicts outcome in heart failure. Biomolecules 13, 410 (2023).
doi: 10.3390/biom13030410
pubmed: 36979345
pmcid: 10046101
Bender, S. B. et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension 65, 1082–1088 (2015).
doi: 10.1161/HYPERTENSIONAHA.114.04912
pubmed: 25712719
Cai, J. et al. Anti-fibrosis effect of relaxin and spironolactone combined on isoprenaline-induced myocardial fibrosis in rats via inhibition of Endothelial-Mesenchymal Transition. Cell. Physiol. Biochem. 41, 1167–1178 (2017).
doi: 10.1159/000464125
pubmed: 28245473
Martinez-Martinez, E. et al. Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage. PLoS One 11, e0166272 (2016).
doi: 10.1371/journal.pone.0166272
pubmed: 27829066
pmcid: 5102450
Kohli, P. et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin. Chem. 58, 257–266 (2012).
doi: 10.1373/clinchem.2011.173369
pubmed: 22096031
Wiśniowska-śmiałek, S. et al. Kinetics of selected serum markers of fibrosis in patients with dilated cardiomyopathy and different grades of diastolic dysfunction of the left ventricle. Cardiol. J. 27, 726 (2020).
doi: 10.5603/CJ.a2018.0143
pubmed: 30484268
pmcid: 8079113
Sharma, U. C. et al. Myocardial and serum Galectin-3 expression dynamics marks post-myocardial infarction cardiac remodelling. Heart Lung Circ. 26, 736–745 (2017).
doi: 10.1016/j.hlc.2016.11.007
pubmed: 28094123
Li, Y. et al. Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction. Sci. Rep. 11, 4297 (2021).
doi: 10.1038/s41598-021-83678-z
pubmed: 33619345
pmcid: 7900233
Paulus, W. J. & Tschöpe, C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62, 263–271 (2013).
doi: 10.1016/j.jacc.2013.02.092
pubmed: 23684677
Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 17, 1321–1360 (2016).
doi: 10.1093/ehjci/jew082
pubmed: 27422899
Mone, P. et al. Empagliflozin improves the MicroRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes. J. Pharmacol. Exp. Ther. 384, 116–122 (2023).
doi: 10.1124/jpet.121.001251
pubmed: 36549862
pmcid: 9827502
Schimmel, K. et al. Natural compound library screening identifies new molecules for the treatment of cardiac fibrosis and diastolic dysfunction. Circulation 141, 751–767 (2020).
doi: 10.1161/CIRCULATIONAHA.119.042559
pubmed: 31948273
pmcid: 7050799
Shi, Y. et al. Clinical implications of plasma Galectin-3 in heart failure with preserved ejection fraction: A meta-analysis. Front. Cardiovasc. Med. https://doi.org/10.3389/fcvm.2022.854501 (2022).
doi: 10.3389/fcvm.2022.854501
pubmed: 36818912
pmcid: 9811315
Dudek, M. et al. sST2 and Heart Failure—Clinical utility and prognosis. J. Clin. Med. 12, 3136 (2023).
doi: 10.3390/jcm12093136
pubmed: 37176577
pmcid: 10179304
Trippel, T. D. et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: Results from the DIAST-CHF study. ESC Heart Fail. 8, 829–841 (2021).
doi: 10.1002/ehf2.13174
pubmed: 33566456
pmcid: 8006663